Zenith Drugs Ltd.

As of March 31, 2026, Zenith Drugs Ltd. carries a market capitalization of 603.64M, placing it among publicly traded companies globally. Its enterprise value stands at 1.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Zenith Drugs Ltd. has 17.15M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Zenith Drugs Ltd. maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 23, 2026, Zenith Drugs Ltd.'s stock has declined approximately 39.26% over the past 52 weeks. The 50-day moving average sits at 42.71, while the 200-day moving average is 44.78.

As of March 31, 2026, Zenith Drugs Ltd. holds 2.61M in cash and equivalents against 551.05M in total debt, resulting in a net debt position of 548.44M. Total book value stands at 733.22M, with working capital of 348.81M providing operational flexibility.